Journal Information
Vol. 6. Issue 1.
Pages 56-57 (January - February 2010)
Share
Share
Download PDF
More article options
Vol. 6. Issue 1.
Pages 56-57 (January - February 2010)
Full text access
Response to rituximab in a patient with Wegener's granulomatosis refractory to conventional therapies
Respuesta a rituximab en un paciente con granulomatosis de Wegener refractaria a terapia convencional
Visits
4461
Inmaculada Macías Fernández
Sección de Reumatología, Hospital Universitario Puerta del Mar, Cádiz, Spain
This item has received
Article information
Abstract

Male patient with a diagnosis of Wegener's granulomatosis associated to anti-proteinase 3 antibodies that improved initially to treatment with high dose glucocorticoids and cyclophosphamide but who relapsed, with a poor response to glucocorticoid treatment, cyclophosphamide, methotrexate and azathioprine. The patient received treatment with rituximab in 4 doses with clinical and radiographic improvement.

Keywords:
Wegener's granulomatosis
Refractory
Rituximab
Biological therapies
Resumen

Se presenta el caso de un paciente con granulomatosis de Wegener asociada a anticuerpos antiproteinasa 3 que tuvo mejoría inicial con dosis altas de glucocorticoides y ciclofosfamida, pero que posteriormente a una recaída no respondió a los mismos medicamentos, ni a metotrexate ni a zatioprina. Por tal motivo, recibió tratamiento con rituximab en 4 dosis, además de glucocorticoides, obteniendo mejoría del cuadro tanto clínica como radiográficamente.

Palabras clave:
Granulomatosis de Wegener
Refractario
Rituximab
Terapias biológicas
Full text is only aviable in PDF
References
[1.]
P. Seo, J.H. Stone.
Update on medium and small vessel vasculitides.
Arthritis Care Res, 53 (2005), pp. 93-99
[2.]
L. Guillevin, J.F. Cordier, F. Lhote, P. Cohen, B. Jarrousse, I. Royer, et al.
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.
[3.]
R.W. Lee, D.P. D’Cruz.
Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Drugs, 68 (2008), pp. 747-770
[4.]
K.R. Chen, J.A. Carlson.
Clinical approach to cutaneous vasculitis.
Am J Clin Dermatol, 9 (2008), pp. 71-92
[5.]
K.A. Keogh, S.R. Ytterberg, F.C. Fervenza, K.A. Carlson, D.R. Schroeder, U. Specks.
Rituximab for refractory Wegener's granulomatosis: report of a prospective, openlabel pilot trial.
Am J Respir Crit Care Med, 173 (2006), pp. 180-187
[6.]
R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A.C. Newland, D. Provan.
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Rheumatology, 45 (2006), pp. 1432-1436
[7.]
D. Sánchez Cano, J.L. Callejas Rubio, N. Ortego Centeno.
Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.
J Clin Rheumatol, 14 (2008), pp. 92-93
[8.]
D. Wayne.
What place for the new biologics in the treatment of necrotising vasculitides.
Clin Exp Rheumatol, 24 (2006), pp. S1-S5
[9.]
P.M. Aries, B. Hellmich, J. Voswinkel, M. Both, B. Nölle, K. Holl-Ulrich, et al.
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.
Ann Rheum Dis, 65 (2006), pp. 853-858
[10.]
B. Brihaye, A. Aouba, C. Pagnoux, P. Cohen, F. Lacassin, L. Guillevin.
Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
Clin Exp Rheumatol, 25 (2007), pp. 23-27
[11.]
R. Jones, C. Savage, C.A. Peh.
Rituximab: a novel remission induction agent in ANCA associated vasculitis. The design of an international, randomised trial (RITUXVAS).
J Am Soc Nephrol, 18 (2007), pp. 972A
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?